APO Research
Talk to an analyst

APO RESEARCH · REPORT

Active Tuberculosis Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Active Tuberculosis Treatment Industry Growth and Trends Forecast to 2032

20 December 2025101 pages

Choose your research edition.

Industry ResearchActive Tuberculosis Treatment Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Active Tuberculosis Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Active Tuberculosis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Active Tuberculosis Treatment Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Active Tuberculosis Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Active Tuberculosis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Active Tuberculosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Active Tuberculosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Active Tuberculosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Active Tuberculosis Treatment include Teva Pharmaceutical Industries Ltd., Sanofi, Johnson & Johnson, Novartis AG, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Macleods Pharmaceuticals Ltd., Lupin and KGaA (Fresenius Kabi), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Active Tuberculosis Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Active Tuberculosis Treatment market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Active Tuberculosis Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Active Tuberculosis Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Active Tuberculosis Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Active Tuberculosis Treatment Market by Company

Teva Pharmaceutical Industries Ltd.

Sanofi

Johnson & Johnson

Novartis AG

Pfizer Inc.

Otsuka Pharmaceutical Co., Ltd.

Macleods Pharmaceuticals Ltd.

Lupin

KGaA (Fresenius Kabi)

FRESENIUS SE & Co

ANI Pharmaceuticals, Inc.

Active Tuberculosis Treatment Segment by Type

Ethambutol

Rifampin

Pyrazinamide

Active Tuberculosis Treatment Segment by Application

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Pharmacies

Active Tuberculosis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Active Tuberculosis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Active Tuberculosis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Active Tuberculosis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Active Tuberculosis Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Active Tuberculosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ethambutol Table 2. Major Company of Rifampin Table 3. Major Company of Pyrazinamide Table 4. Global Active Tuberculosis Treatment Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Active Tuberculosis Treatment Sales by Type (2021-2026) & (k units) Table 6. Global Active Tuberculosis Treatment Sales Market Share in Volume by Type (2021-2026) Table 7. Global Active Tuberculosis Treatment Sales by Type (2021-2026) & (US$ Million) Table 8. Global Active Tuberculosis Treatment Sales Market Share in Value by Type (2021-2026) Table 9. Global Active Tuberculosis Treatment Price by Type (2021-2026) & (US$/unit) Table 10. Global Active Tuberculosis Treatment Sales by Type (2027-2032) & (k units) Table 11. Global Active Tuberculosis Treatment Sales Market Share in Volume by Type (2027-2032) Table 12. Global Active Tuberculosis Treatment Sales by Type (2027-2032) & (US$ Million) Table 13. Global Active Tuberculosis Treatment Sales Market Share in Value by Type (2027-2032) Table 14. Global Active Tuberculosis Treatment Price by Type (2027-2032) & (US$/unit) Table 15. North America Active Tuberculosis Treatment Sales by Type (2021-2026) & (k units) Table 16. North America Active Tuberculosis Treatment Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Active Tuberculosis Treatment Sales by Type (2021-2026) & (k units) Table 18. Europe Active Tuberculosis Treatment Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Active Tuberculosis Treatment Sales by Type (2021-2026) & (k units) Table 20. Asia-Pacific Active Tuberculosis Treatment Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Active Tuberculosis Treatment Sales by Type (2021-2026) & (k units) Table 22. Latin America Active Tuberculosis Treatment Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Active Tuberculosis Treatment Sales by Type (2021-2026) & (k units) Table 24. Middle East and Africa Active Tuberculosis Treatment Sales by Type (2021-2026) & (US$ Million) Table 25. Active Tuberculosis Treatment Industry Trends Table 26. Active Tuberculosis Treatment Industry Drivers Table 27. Active Tuberculosis Treatment Industry Opportunities and Challenges Table 28. Active Tuberculosis Treatment Industry Restraints Table 29. Global Active Tuberculosis Treatment Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Active Tuberculosis Treatment Revenue Market Share by Company (2021-2026) Table 31. Global Active Tuberculosis Treatment Sales by Company (2021-2026) & (k units) Table 32. Global Active Tuberculosis Treatment Sales Share by Company (2021-2026) Table 33. Global Active Tuberculosis Treatment Market Price by Company (2021-2026) & (US$/unit) Table 34. Global Active Tuberculosis Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Active Tuberculosis Treatment Major Company Production Sites and Headquarters Table 36. Global Active Tuberculosis Treatment Company, Product Type & Application Table 37. Global Active Tuberculosis Treatment Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Active Tuberculosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Active Tuberculosis Treatment Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Active Tuberculosis Treatment Sales by Region (2021-2026) & (k units) Table 42. Global Active Tuberculosis Treatment Sales Market Share in Volume by Region (2021-2026) Table 43. Global Active Tuberculosis Treatment Sales by Region (2021-2026) & (US$ Million) Table 44. Global Active Tuberculosis Treatment Sales Market Share in Value by Region (2021-2026) Table 45. Global Active Tuberculosis Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Global Active Tuberculosis Treatment Sales by Region (2027-2032) & (k units) Table 47. Global Active Tuberculosis Treatment Sales Market Share in Volume by Region (2027-2032) Table 48. Global Active Tuberculosis Treatment Sales by Region (2027-2032) & (US$ Million) Table 49. Global Active Tuberculosis Treatment Sales Market Share in Value by Region (2027-2032) Table 50. Global Active Tuberculosis Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 51. Global Active Tuberculosis Treatment Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Active Tuberculosis Treatment Sales by Application (2021-2026) & (k units) Table 53. Global Active Tuberculosis Treatment Sales Market Share in Volume by Application (2021-2026) Table 54. Global Active Tuberculosis Treatment Sales by Application (2021-2026) & (US$ Million) Table 55. Global Active Tuberculosis Treatment Sales Market Share in Value by Application (2021-2026) Table 56. Global Active Tuberculosis Treatment Price by Application (2021-2026) & (US$/unit) Table 57. Global Active Tuberculosis Treatment Sales by Application (2027-2032) & (k units) Table 58. Global Active Tuberculosis Treatment Sales Market Share in Volume by Application (2027-2032) Table 59. Global Active Tuberculosis Treatment Sales by Application (2027-2032) & (US$ Million) Table 60. Global Active Tuberculosis Treatment Sales Market Share in Value by Application (2027-2032) Table 61. Global Active Tuberculosis Treatment Price by Application (2027-2032) & (US$/unit) Table 62. North America Active Tuberculosis Treatment Sales by Application (2021-2026) & (k units) Table 63. North America Active Tuberculosis Treatment Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Active Tuberculosis Treatment Sales by Application (2021-2026) & (k units) Table 65. Europe Active Tuberculosis Treatment Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Active Tuberculosis Treatment Sales by Application (2021-2026) & (k units) Table 67. Asia-Pacific Active Tuberculosis Treatment Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Active Tuberculosis Treatment Sales by Application (2021-2026) & (k units) Table 69. Latin America Active Tuberculosis Treatment Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Active Tuberculosis Treatment Sales by Application (2021-2026) & (k units) Table 71. Middle East and Africa Active Tuberculosis Treatment Sales by Application (2021-2026) & (US$ Million) Table 72. Teva Pharmaceutical Industries Ltd. Company Information Table 73. Teva Pharmaceutical Industries Ltd. Business Overview Table 74. Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Product Portfolio Table 76. Teva Pharmaceutical Industries Ltd. Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Sanofi Active Tuberculosis Treatment Product Portfolio Table 81. Sanofi Recent Development Table 82. Johnson & Johnson Company Information Table 83. Johnson & Johnson Business Overview Table 84. Johnson & Johnson Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Johnson & Johnson Active Tuberculosis Treatment Product Portfolio Table 86. Johnson & Johnson Recent Development Table 87. Novartis AG Company Information Table 88. Novartis AG Business Overview Table 89. Novartis AG Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Novartis AG Active Tuberculosis Treatment Product Portfolio Table 91. Novartis AG Recent Development Table 92. Pfizer Inc. Company Information Table 93. Pfizer Inc. Business Overview Table 94. Pfizer Inc. Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Pfizer Inc. Active Tuberculosis Treatment Product Portfolio Table 96. Pfizer Inc. Recent Development Table 97. Otsuka Pharmaceutical Co., Ltd. Company Information Table 98. Otsuka Pharmaceutical Co., Ltd. Business Overview Table 99. Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Product Portfolio Table 101. Otsuka Pharmaceutical Co., Ltd. Recent Development Table 102. Macleods Pharmaceuticals Ltd. Company Information Table 103. Macleods Pharmaceuticals Ltd. Business Overview Table 104. Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Product Portfolio Table 106. Macleods Pharmaceuticals Ltd. Recent Development Table 107. Lupin Company Information Table 108. Lupin Business Overview Table 109. Lupin Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Lupin Active Tuberculosis Treatment Product Portfolio Table 111. Lupin Recent Development Table 112. KGaA (Fresenius Kabi) Company Information Table 113. KGaA (Fresenius Kabi) Business Overview Table 114. KGaA (Fresenius Kabi) Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. KGaA (Fresenius Kabi) Active Tuberculosis Treatment Product Portfolio Table 116. KGaA (Fresenius Kabi) Recent Development Table 117. FRESENIUS SE & Co Company Information Table 118. FRESENIUS SE & Co Business Overview Table 119. FRESENIUS SE & Co Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. FRESENIUS SE & Co Active Tuberculosis Treatment Product Portfolio Table 121. FRESENIUS SE & Co Recent Development Table 122. ANI Pharmaceuticals, Inc. Company Information Table 123. ANI Pharmaceuticals, Inc. Business Overview Table 124. ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Product Portfolio Table 126. ANI Pharmaceuticals, Inc. Recent Development Table 127. North America Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 128. North America Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 129. North America Active Tuberculosis Treatment Sales Market Share by Country (2021-2026) Table 130. North America Active Tuberculosis Treatment Sales Forecast by Country (2027-2032) & (k units) Table 131. North America Active Tuberculosis Treatment Sales Market Share Forecast by Country (2027-2032) Table 132. North America Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. North America Active Tuberculosis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 134. North America Active Tuberculosis Treatment Market Share by Country (2021-2026) Table 135. North America Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. North America Active Tuberculosis Treatment Market Share Forecast by Country (2027-2032) Table 137. Europe Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 138. Europe Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 139. Europe Active Tuberculosis Treatment Sales Market Share by Country (2021-2026) Table 140. Europe Active Tuberculosis Treatment Sales Forecast by Country (2027-2032) & (k units) Table 141. Europe Active Tuberculosis Treatment Sales Market Share Forecast by Country (2027-2032) Table 142. Europe Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Europe Active Tuberculosis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 144. Europe Active Tuberculosis Treatment Market Share by Country (2021-2026) Table 145. Europe Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Europe Active Tuberculosis Treatment Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 149. Asia-Pacific Active Tuberculosis Treatment Sales Market Share by Country (2021-2026) Table 150. Asia-Pacific Active Tuberculosis Treatment Sales Forecast by Country (2027-2032) & (k units) Table 151. Asia-Pacific Active Tuberculosis Treatment Sales Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific Active Tuberculosis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 154. Asia-Pacific Active Tuberculosis Treatment Market Share by Country (2021-2026) Table 155. Asia-Pacific Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Asia-Pacific Active Tuberculosis Treatment Market Share Forecast by Country (2027-2032) Table 157. Latin America Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 158. Latin America Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 159. Latin America Active Tuberculosis Treatment Sales Market Share by Country (2021-2026) Table 160. Latin America Active Tuberculosis Treatment Sales Forecast by Country (2027-2032) & (k units) Table 161. Latin America Active Tuberculosis Treatment Sales Market Share Forecast by Country (2027-2032) Table 162. Latin America Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Latin America Active Tuberculosis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 164. Latin America Active Tuberculosis Treatment Market Share by Country (2021-2026) Table 165. Latin America Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Latin America Active Tuberculosis Treatment Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 169. Middle East and Africa Active Tuberculosis Treatment Sales Market Share by Country (2021-2026) Table 170. Middle East and Africa Active Tuberculosis Treatment Sales Forecast by Country (2027-2032) & (k units) Table 171. Middle East and Africa Active Tuberculosis Treatment Sales Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa Active Tuberculosis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 174. Middle East and Africa Active Tuberculosis Treatment Market Share by Country (2021-2026) Table 175. Middle East and Africa Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Middle East and Africa Active Tuberculosis Treatment Market Share Forecast by Country (2027-2032) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Active Tuberculosis Treatment Distributors List Table 180. Active Tuberculosis Treatment Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Active Tuberculosis Treatment Image Figure 2. Global Active Tuberculosis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Active Tuberculosis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Active Tuberculosis Treatment Sales (2021-2032) & (k units) Figure 5. Ethambutol Image Figure 6. Global Ethambutol Sales YoY Growth (2021-2032) & (k units) Figure 7. Rifampin Image Figure 8. Global Rifampin Sales YoY Growth (2021-2032) & (k units) Figure 9. Pyrazinamide Image Figure 10. Global Pyrazinamide Sales YoY Growth (2021-2032) & (k units) Figure 11. Global Active Tuberculosis Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Active Tuberculosis Treatment Market Share by Type 2025 VS 2032 Figure 13. North America Active Tuberculosis Treatment Sales Market Share in Volume by Type in 2025 Figure 14. North America Active Tuberculosis Treatment Sales Market Share in Value by Type in 2025 Figure 15. Europe Active Tuberculosis Treatment Sales Market Share in Volume by Type in 2025 Figure 16. Europe Active Tuberculosis Treatment Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Active Tuberculosis Treatment Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Active Tuberculosis Treatment Sales Market Share in Value by Type in 2025 Figure 19. Latin America Active Tuberculosis Treatment Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Active Tuberculosis Treatment Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Active Tuberculosis Treatment Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Active Tuberculosis Treatment Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Active Tuberculosis Treatment Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Pharmacies Image Figure 26. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 27. Drug Stores and Retail Pharmacies Image Figure 28. Global Drug Stores and Retail Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 29. Online Pharmacies Image Figure 30. Global Online Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Active Tuberculosis Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Active Tuberculosis Treatment Market Share by Application 2025 VS 2032 Figure 33. North America Active Tuberculosis Treatment Sales Market Share in Volume by Application in 2025 Figure 34. North America Active Tuberculosis Treatment Sales Market Share in Value by Application in 2025 Figure 35. Europe Active Tuberculosis Treatment Sales Market Share in Volume by Application in 2025 Figure 36. Europe Active Tuberculosis Treatment Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Active Tuberculosis Treatment Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Active Tuberculosis Treatment Sales Market Share in Value by Application in 2025 Figure 39. Latin America Active Tuberculosis Treatment Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Active Tuberculosis Treatment Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Active Tuberculosis Treatment Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Active Tuberculosis Treatment Sales Market Share in Value by Application in 2025 Figure 43. North America Active Tuberculosis Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Active Tuberculosis Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Active Tuberculosis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Active Tuberculosis Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Active Tuberculosis Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Active Tuberculosis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Active Tuberculosis Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Active Tuberculosis Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Active Tuberculosis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Active Tuberculosis Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Active Tuberculosis Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Active Tuberculosis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Active Tuberculosis Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Active Tuberculosis Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Active Tuberculosis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Active Tuberculosis Treatment Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Active Tuberculosis Treatment Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Ethambutol
  • Rifampin
  • Pyrazinamide
Applications
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Lupin
  • KGaA (Fresenius Kabi)
  • FRESENIUS SE & Co
  • ANI Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Active Tuberculosis Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Active Tuberculosis Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Active Tuberculosis Treatment Market by Type
  6. 1.3.1 Ethambutol
  7. 1.3.2 Rifampin
  8. 1.3.3 Pyrazinamide
  9. 1.4 Global Active Tuberculosis Treatment Market Size by Type
  10. 1.4.1 Global Active Tuberculosis Treatment Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Active Tuberculosis Treatment Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Active Tuberculosis Treatment Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Active Tuberculosis Treatment Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Active Tuberculosis Treatment Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Active Tuberculosis Treatment Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Active Tuberculosis Treatment Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Active Tuberculosis Treatment Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Active Tuberculosis Treatment Industry Trends
  2. 2.2 Active Tuberculosis Treatment Industry Drivers
  3. 2.3 Active Tuberculosis Treatment Industry Opportunities and Challenges
  4. 2.4 Active Tuberculosis Treatment Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Active Tuberculosis Treatment Revenue (2021-2026)
  2. 3.2 Global Top Players by Active Tuberculosis Treatment Sales (2021-2026)
  3. 3.3 Global Top Players by Active Tuberculosis Treatment Price (2021-2026)
  4. 3.4 Global Active Tuberculosis Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Active Tuberculosis Treatment Major Company Production Sites & Headquarters
  6. 3.6 Global Active Tuberculosis Treatment Company, Product Type & Application
  7. 3.7 Global Active Tuberculosis Treatment Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Active Tuberculosis Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Active Tuberculosis Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Active Tuberculosis Treatment Tier 1, Tier 2, and Tier 3
4 Active Tuberculosis Treatment Regional Status and Outlook
  1. 4.1 Global Active Tuberculosis Treatment Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Active Tuberculosis Treatment Historic Market Size by Region
  3. 4.2.1 Global Active Tuberculosis Treatment Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Active Tuberculosis Treatment Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Active Tuberculosis Treatment Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Active Tuberculosis Treatment Forecasted Market Size by Region
  7. 4.3.1 Global Active Tuberculosis Treatment Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Active Tuberculosis Treatment Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Active Tuberculosis Treatment Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Active Tuberculosis Treatment by Application
  1. 5.1 Active Tuberculosis Treatment Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Drug Stores and Retail Pharmacies
  4. 5.1.3 Online Pharmacies
  5. 5.2 Global Active Tuberculosis Treatment Market Size by Application
  6. 5.2.1 Global Active Tuberculosis Treatment Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Active Tuberculosis Treatment Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Active Tuberculosis Treatment Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Active Tuberculosis Treatment Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Active Tuberculosis Treatment Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Active Tuberculosis Treatment Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Active Tuberculosis Treatment Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Active Tuberculosis Treatment Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries Ltd.
  2. 6.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Active Tuberculosis Treatment Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Johnson & Johnson
  14. 6.3.1 Johnson & Johnson Company Information
  15. 6.3.2 Johnson & Johnson Business Overview
  16. 6.3.3 Johnson & Johnson Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Johnson & Johnson Active Tuberculosis Treatment Product Portfolio
  18. 6.3.5 Johnson & Johnson Recent Developments
  19. 6.4 Novartis AG
  20. 6.4.1 Novartis AG Company Information
  21. 6.4.2 Novartis AG Business Overview
  22. 6.4.3 Novartis AG Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis AG Active Tuberculosis Treatment Product Portfolio
  24. 6.4.5 Novartis AG Recent Developments
  25. 6.5 Pfizer Inc.
  26. 6.5.1 Pfizer Inc. Company Information
  27. 6.5.2 Pfizer Inc. Business Overview
  28. 6.5.3 Pfizer Inc. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Inc. Active Tuberculosis Treatment Product Portfolio
  30. 6.5.5 Pfizer Inc. Recent Developments
  31. 6.6 Otsuka Pharmaceutical Co., Ltd.
  32. 6.6.1 Otsuka Pharmaceutical Co., Ltd. Company Information
  33. 6.6.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
  34. 6.6.3 Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Product Portfolio
  36. 6.6.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
  37. 6.7 Macleods Pharmaceuticals Ltd.
  38. 6.7.1 Macleods Pharmaceuticals Ltd. Company Information
  39. 6.7.2 Macleods Pharmaceuticals Ltd. Business Overview
  40. 6.7.3 Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Product Portfolio
  42. 6.7.5 Macleods Pharmaceuticals Ltd. Recent Developments
  43. 6.8 Lupin
  44. 6.8.1 Lupin Company Information
  45. 6.8.2 Lupin Business Overview
  46. 6.8.3 Lupin Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Lupin Active Tuberculosis Treatment Product Portfolio
  48. 6.8.5 Lupin Recent Developments
  49. 6.9 KGaA (Fresenius Kabi)
  50. 6.9.1 KGaA (Fresenius Kabi) Company Information
  51. 6.9.2 KGaA (Fresenius Kabi) Business Overview
  52. 6.9.3 KGaA (Fresenius Kabi) Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 KGaA (Fresenius Kabi) Active Tuberculosis Treatment Product Portfolio
  54. 6.9.5 KGaA (Fresenius Kabi) Recent Developments
  55. 6.10 FRESENIUS SE & Co
  56. 6.10.1 FRESENIUS SE & Co Company Information
  57. 6.10.2 FRESENIUS SE & Co Business Overview
  58. 6.10.3 FRESENIUS SE & Co Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 FRESENIUS SE & Co Active Tuberculosis Treatment Product Portfolio
  60. 6.10.5 FRESENIUS SE & Co Recent Developments
  61. 6.11 ANI Pharmaceuticals, Inc.
  62. 6.11.1 ANI Pharmaceuticals, Inc. Company Information
  63. 6.11.2 ANI Pharmaceuticals, Inc. Business Overview
  64. 6.11.3 ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Product Portfolio
  66. 6.11.5 ANI Pharmaceuticals, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Active Tuberculosis Treatment Sales by Country
  2. 7.1.1 North America Active Tuberculosis Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Active Tuberculosis Treatment Sales by Country (2021-2026)
  4. 7.1.3 North America Active Tuberculosis Treatment Sales Forecast by Country (2027-2032)
  5. 7.2 North America Active Tuberculosis Treatment Market Size by Country
  6. 7.2.1 North America Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Active Tuberculosis Treatment Market Size by Country (2021-2026)
  8. 7.2.3 North America Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Active Tuberculosis Treatment Sales by Country
  2. 8.1.1 Europe Active Tuberculosis Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Active Tuberculosis Treatment Sales by Country (2021-2026)
  4. 8.1.3 Europe Active Tuberculosis Treatment Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Active Tuberculosis Treatment Market Size by Country
  6. 8.2.1 Europe Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Active Tuberculosis Treatment Market Size by Country (2021-2026)
  8. 8.2.3 Europe Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Active Tuberculosis Treatment Sales by Country
  2. 9.1.1 Asia-Pacific Active Tuberculosis Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Active Tuberculosis Treatment Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Active Tuberculosis Treatment Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Active Tuberculosis Treatment Market Size by Country
  6. 9.2.1 Asia-Pacific Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Active Tuberculosis Treatment Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Active Tuberculosis Treatment Sales by Country
  2. 10.1.1 South America Active Tuberculosis Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Active Tuberculosis Treatment Sales by Country (2021-2026)
  4. 10.1.3 South America Active Tuberculosis Treatment Sales Forecast by Country (2027-2032)
  5. 10.2 South America Active Tuberculosis Treatment Market Size by Country
  6. 10.2.1 South America Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Active Tuberculosis Treatment Market Size by Country (2021-2026)
  8. 10.2.3 South America Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Active Tuberculosis Treatment Sales by Country
  2. 11.1.1 Middle East and Africa Active Tuberculosis Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Active Tuberculosis Treatment Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Active Tuberculosis Treatment Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Active Tuberculosis Treatment Market Size by Country
  6. 11.2.1 Middle East and Africa Active Tuberculosis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Active Tuberculosis Treatment Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Active Tuberculosis Treatment Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Active Tuberculosis Treatment Value Chain Analysis
  2. 12.1.1 Active Tuberculosis Treatment Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Active Tuberculosis Treatment Production Mode & Process
  7. 12.2 Active Tuberculosis Treatment Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Active Tuberculosis Treatment Distributors
  10. 12.2.3 Active Tuberculosis Treatment Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst